| 1 |
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
Philip W. Kantoff, Celestia S. Higano, Neal D. Shore et al. · New England Journal of Medicine
Open access |
28 Jul 2010 |
5,577 |
| 2 |
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Howard I. Scher, Karim S. Fizazi, Fred Saad et al. · New England Journal of Medicine
Open access |
15 Aug 2012 |
4,645 |
| 3 |
Olaparib for Metastatic Castration-Resistant Prostate Cancer
Johann Sebastian De Bono, Joaquı́n Mateo, Karim S. Fizazi et al. · New England Journal of Medicine
Open access |
28 Apr 2020 |
2,322 |
| 4 |
Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study
Karim S. Fizazi, Michael Anthony Carducci, Matthew R. Smith et al. · The Lancet
Open access |
26 Feb 2011 |
1,981 |
| 5 |
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study
Charles J. Ryan et al. · The Lancet Oncology
|
15 Jan 2015 |
1,378 |
| 6 |
ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer
Andrew J. Armstrong, Russell Zelig Szmulewitz, Daniel Peter Petrylak et al. · Journal of Clinical Oncology
Open access |
22 Jul 2019 |
1,239 |
| 7 |
Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer
Maha Hussain, Karim S. Fizazi, Fred Saad et al. · New England Journal of Medicine
Open access |
27 Jun 2018 |
1,062 |
| 8 |
Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer
Karim S. Fizazi, Neal D. Shore, Teuvo L.J. Tammela et al. · New England Journal of Medicine
Open access |
14 Feb 2019 |
946 |
| 9 |
Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases
Fred Saad, Janet Elizabeth Brown, Catherine H. Van Poznak et al. · Annals of Oncology
Open access |
11 Oct 2011 |
825 |
| 10 |
Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial
Matthew R. Smith et al. · The Lancet
Open access |
17 Nov 2011 |
802 |
| 11 |
Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer
Maha Hussain, Joaquı́n Mateo, Karim S. Fizazi et al. · New England Journal of Medicine
Open access |
20 Sep 2020 |
792 |
| 12 |
Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017
Silke Gillessen et al. · European Urology
Open access |
24 Jun 2017 |
644 |
| 13 |
The efficacy and safety of degarelix: a 12‐month, comparative, randomized, open‐label, parallel‐group phase III study in patients with prostate cancer
Laurence H. Klotz, LAURENT BOCCON-GIBOD, Neal D. Shore et al. · British Journal of Urology
Open access |
21 Nov 2008 |
621 |
| 14 |
Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial
Neeraj Agarwal et al. · The Lancet
Open access |
4 Jun 2023 |
533 |
| 15 |
MLPerf Inference Benchmark
Vijay Janapa Reddi et al.
Conference paper |
May 2020 |
517 |
| 16 |
Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial
Stephen Anthony Boorjian et al. · The Lancet Oncology
Open access |
27 Nov 2020 |
476 |
| 17 |
Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer
Neal D. Shore, Fred Saad, Michael S. Cookson et al. · New England Journal of Medicine
Open access |
29 May 2020 |
449 |
| 18 |
Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer
Cora Nanette Sternberg, Karim S. Fizazi, Fred Saad et al. · New England Journal of Medicine
Open access |
29 May 2020 |
435 |
| 19 |
Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer
Noel William Clarke et al. · NEJM Evidence
|
3 Jun 2022 |
424 |
| 20 |
A Multi-institutional Prospective Trial in the USA Confirms that the 4Kscore Accurately Identifies Men with High-grade Prostate Cancer
Dipen J. Parekh et al. · European Urology
|
27 Oct 2014 |
418 |
| 21 |
Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019
Silke Gillessen et al. · European Urology
Open access |
27 Jan 2020 |
400 |
| 22 |
Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide
Karim S. Fizazi, Neal D. Shore, Teuvo L.J. Tammela et al. · New England Journal of Medicine
Open access |
9 Sep 2020 |
371 |
| 23 |
Nonstoichiometry in Undoped BaTiO 3
N.‐H. CHAN, R. K. Sharma, D. M. Smyth · Journal of the American Ceramic Society
|
Sep 1981 |
341 |
| 24 |
177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial
Michael J. Morris et al. · The Lancet
Open access |
Sep 2024 |
333 |
| 25 |
Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015
Silke Gillessen et al. · Annals of Oncology
Open access |
4 Jun 2015 |
324 |
| 26 |
Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer
Stephen J. Freedland, Murilo de Almeida Luz, Ugo De Giorgi et al. · New England Journal of Medicine
|
18 Oct 2023 |
315 |
| 27 |
Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial
Fred Saad, Noel William Clarke, Mototsugu Oya et al. · The Lancet Oncology
Open access |
12 Sep 2023 |
315 |
| 28 |
Improved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer
Andrew J. Armstrong, Arun Azad, Taro Iguchi et al. · Journal of Clinical Oncology
Open access |
14 Apr 2022 |
313 |
| 29 |
Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study
Neal D. Shore, Simon Chowdhury, Arnauld A. Villers et al. · The Lancet Oncology
|
13 Jan 2016 |
289 |
| 30 |
A Prospective Adaptive Utility Trial to Validate Performance of a Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer in Patients with Prostate-specific Antigen 2–10 ng/ml at Initial Biopsy
James McKiernan, Michael Joseph Donovan, Eric Margolis et al. · European Urology
Open access |
17 Sep 2018 |
288 |
| 31 |
Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer
James L. Gulley, Michael Borre, Nicholas J. Vogelzang et al. · Journal of Clinical Oncology
Open access |
28 Feb 2019 |
286 |
| 32 |
Five year results of the prospective randomized controlled prostatic urethral L.I.F.T. study.
Claus G. Roehrborn, Jack Barkin, Steven N. Gange et al. · PubMed
|
Jun 2017 |
279 |
| 33 |
The Prostatic Urethral Lift for the Treatment of Lower Urinary Tract Symptoms Associated with Prostate Enlargement Due to Benign Prostatic Hyperplasia: The L.I.F.T. Study
Claus G. Roehrborn, Steven N. Gange, Neal D. Shore et al. · The Journal of Urology
|
11 Jun 2013 |
277 |
| 34 |
Updated Interim Efficacy Analysis and Long-term Safety of Abiraterone Acetate in Metastatic Castration-resistant Prostate Cancer Patients Without Prior Chemotherapy (COU-AA-302)
Dana E. Rathkopf et al. · European Urology
Open access |
6 Mar 2014 |
275 |
| 35 |
Nonstoichiometry in Acceptor‐Doped BaTiO 3
N.‐H. CHAN, R. K. Sharma, D. M. Smyth · Journal of the American Ceramic Society
|
Mar 1982 |
271 |
| 36 |
Minimally Invasive Prostate Convective Water Vapor Energy Ablation: A Multicenter, Randomized, Controlled Study for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia
Kevin T. McVary, Steven N. Gange, MARC C. GITTELMAN et al. · The Journal of Urology
|
22 Nov 2015 |
255 |
| 37 |
Targeted Alpha Therapy, an Emerging Class of Cancer Agents
Targeted Alpha Therapy Working Group, Christopher T. Parker, Valerie J. Lewington et al. · JAMA Oncology
|
19 Oct 2018 |
247 |
| 38 |
Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS Trial
Maha Hussain, Bertrand F. TOMBAL, Fred Saad et al. · Journal of Clinical Oncology
Open access |
16 Feb 2023 |
230 |
| 39 |
Final 5-Year Outcomes of the Multicenter Randomized Sham-Controlled Trial of a Water Vapor Thermal Therapy for Treatment of Moderate to Severe Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia
Kevin T. McVary, MARC C. GITTELMAN, Kenneth A. Goldberg et al. · The Journal of Urology
|
19 Apr 2021 |
209 |
| 40 |
Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies
E. David Crawford, Celestia S. Higano, Neal D. Shore et al. · The Journal of Urology
|
18 Jul 2015 |
193 |
| 41 |
Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer
Alison Stopeck, Karim S. Fizazi, Jean-Jacques Body et al. · Supportive Care in Cancer
Open access |
2 Sep 2015 |
190 |
| 42 |
Darolutamide in Combination With Androgen-Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer From the Phase III ARANOTE Trial
Fred Saad et al. · Journal of Clinical Oncology
Open access183 authors |
16 Sep 2024 |
170 |
| 43 |
Management of patients with advanced prostate cancer—metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022
Silke Gillessen et al. · European Journal of Cancer
Open access118 authors |
2 Mar 2023 |
166 |
| 44 |
Managing Nonmetastatic Castration-resistant Prostate Cancer
Joaquı́n Mateo, Karim S. Fizazi, Silke Gillessen et al. · European Urology
Open access |
14 Aug 2018 |
165 |
| 45 |
Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial
Ethan Basch, Karen A. Autio, Charles J. Ryan et al. · The Lancet Oncology
|
25 Sep 2013 |
154 |
| 46 |
A Phase III Extension Trial With a 1-Arm Crossover From Leuprolide to Degarelix: Comparison of Gonadotropin-Releasing Hormone Agonist and Antagonist Effect on Prostate Cancer
E. David Crawford, Bertrand F. TOMBAL, Kurt Miller et al. · The Journal of Urology
|
26 Jul 2011 |
154 |
| 47 |
Hypocalcaemia in patients with metastatic bone disease treated with denosumab
Jean-Jacques Body, Henry G. Bone, Richard H. De Boer et al. · European Journal of Cancer
Open access |
17 Jun 2015 |
153 |
| 48 |
Biochemical recurrence in patients with prostate cancer after primary definitive therapy: treatment based on risk stratification
Neal D. Shore, Judd W. Moul, Kenneth J. Pienta et al. · Prostate Cancer and Prostatic Diseases
Open access |
7 Sep 2023 |
151 |
| 49 |
Androgen Receptor Targeted Treatments of Prostate Cancer: 35 Years of Progress with Antiandrogens
E. David Crawford, Paul F. Schellhammer, David G. McLeod et al. · The Journal of Urology
|
3 May 2018 |
151 |
| 50 |
Additional Analysis of the Secondary End Point of Biochemical Recurrence Rate in a Phase 3 Trial (CS21) Comparing Degarelix 80mg Versus Leuprolide in Prostate Cancer Patients Segmented by Baseline Characteristics
Bertrand F. TOMBAL, Kurt Miller, LAURENT BOCCON-GIBOD et al. · European Urology
|
21 Nov 2009 |
148 |